Call Us Today at 508-231-8842        EMERGENCY

November 14, 2019, Ashland, MA – MEDIcept Inc., a leading international Quality and Regulatory consulting firm focused on medical device and invitro diagnostics, and ACMP Consulting, Acton, MA have entered into an agreement to provide Clinical Research Organization (CRO) services for early phase, pre-, and post-market studies to the healthcare industry.

The MEDIcept/ACMP agreement will offer medical device companies full clinical operations support, including:

  • protocol development,
  • site start-up activities,
  • IRB communication,
  • trial monitoring,
  • biostatistics,
  • data management,
  • data and safety monitoring and Committees (CEC and DSMB),
  • medical writing, and
  • other consulting services such vendor management and clinical audits.

MEDIcept President, David Rothkopf, said: “MEDIcept plays an important role in the medical device and biotech industry as a champion of quality and regulatory practices. The new relationship expands and strengthens our services to our customer base to develop products and services that will protect and improve human health while minimizing inefficiencies to save time and reduce unnecessary costs. With the addition of CRO service we can better develop efficient and effective strategies for the submission and approval of devices.”

Dr. Adelina Paunescu, Principal of ACMP said: “The complementary synergies between our companies will increase service offerings. ACMP will be able to leverage MEDIcept’ s global relationships to expand our contract research capabilities and better serve our clients with design and execution of clinical trials. With this collaboration, MEDIcept and ACMP can serve our clients with full scope, from development, clinical trial data and regulatory authorities’ submissions to a successful clearance and approval.”

Sign up to receive our Newsletters!

The Latest News

FDA Updates Special 510(k) Guidance

FDA’s Special 510(k) submission process has been around for years as an expedited method to demonstrate that the device to be marketed is at least as safe and effective (i.e., substantially equivalent), to a legally-marketed device not subject to the Premarket Approval (PMA) process. In September 2019, a modified version of this program was published to create a streamlined review of technological changes made to a manufacturer’s own cleared device which leveraged design control requirements....

Metal Implants: FDA’s November, 2019 Immunology Devices Panel Meeting

The Immunology Devices Panel of the FDA’s Medical Device Advisory Committee met in November to discuss the topic of immunological responses to metal-containing products regulated as medical devices. The panel focused on metal-containing implants as well as dental amalgam. Recent post-market issues with some metal-on-metal orthopedic implants and gynecological metal-containing implants have raised questions about the potential for some patients to develop unexpected or heightened biological...

Quality Systems in Motion, Inc. (QSIM) is now part of MEDIcept Inc.

For Immediate Release Ashland, MA: MEDIcept Inc, an international quality, regulatory, and clinical consulting firm focused on medical device and in-vitro diagnostics (IVD), and QSIM, a US-based privately held consulting firm specializing in medical device/biotechnology, announces the merger of the two companies. QSIM, under the direction of Brian Markham, President, specialized in providing leadership and resources for organizations undergoing significant quality system change due to...